term
microbiom
refer
ecolog
commun
commens
symbiot
pathogen
organ
share
bodi
space
well
complex
interact
microb
host
gastrointestin
microbiom
compos
trillion
microorgan
extens
studi
convers
epitheli
surfac
lower
respiratori
tract
one
least
popul
surfac
human
bodi
histor
describ
steril
incorrectli
held
doctrin
aros
primarili
challeng
directli
sampl
lower
airway
limit
bacteri
cultur
prevent
isol
identif
microb
transit
culturedepend
cultureindepend
methodolog
reveal
complex
dynam
commun
microb
harbour
respiratori
tract
nowaday
highthroughput
dna
sequenc
technolog
enabl
rapid
identif
complex
bacteri
commun
includ
organ
cultur
base
sequenc
similar
highli
conserv
gene
ribosom
rna
gene
rrna
result
research
start
examin
lung
microbiom
healthi
subject
well
individu
affect
chronic
respiratori
diseas
chronic
obstruct
pulmonari
diseas
copd
bronchiectasi
cystic
fibrosi
asthma
interstiti
lung
diseas
ild
variou
complex
popul
bacteria
fungi
virus
identifi
idiopath
pulmonari
fibrosi
ipf
chronic
progress
ultim
fatal
fibrot
ild
unknown
caus
primarili
affect
older
adult
mechan
underli
ipf
incomplet
understood
diseas
believ
result
abnorm
woundheal
mechan
follow
repetit
alveolar
microinjuri
smoke
microaspir
gastric
content
infect
among
other
repres
plausibl
put
trigger
fibrot
respons
specif
infecti
agent
includ
virus
bacteria
induc
alveolar
epitheli
cell
damag
apoptosi
modul
host
respons
injuri
addit
mutat
gene
encod
mucin
requir
normal
macrophag
function
effect
mucociliari
clearanc
bacteria
mice
associ
increas
risk
develop
familiar
sporad
ipf
suggest
bacteria
may
act
cofactor
fibrosi
initi
genet
predispos
individu
infect
may
also
play
role
diseas
progress
patient
ipf
activ
infect
carri
high
morbid
mortal
wherea
immunosuppress
eg
combin
prednison
azathioprin
nacetylcystein
increas
risk
death
hospit
notabl
util
corticosteroid
ipf
particularli
acut
phase
diseas
question
well
panther
trial
review
summar
critic
discuss
current
knowledg
interplay
lung
microbiom
ipf
emphasi
potenti
role
diseas
develop
progress
acut
exacerb
histor
studi
investig
role
chronic
infect
either
etiolog
agent
cofactor
develop
ipf
focus
primarili
virus
ueda
colleagu
evalu
preval
serum
antibodi
hepat
c
viru
hcv
patient
ipf
n
found
significantli
higher
compar
agegendermatch
control
n
versu
respect
addit
cohort
patient
infect
hcv
aras
colleagu
observ
cumul
incid
ipf
respect
compar
case
ipf
control
group
patient
hepat
b
viru
hbv
p
risk
develop
ipf
particularli
high
among
heavi
smoker
individu
older
year
patient
liver
cirrhosi
howev
hcv
associ
ipf
consist
observ
human
herp
virus
hhv
larg
famili
dna
virus
includ
herp
simplex
viru
type
epsteinbarr
viru
ebv
cytomegaloviru
cmv
receiv
attent
caus
factor
ipf
mainli
abil
caus
lifelong
latent
infect
alveolar
epithelium
reactiv
older
individu
first
studi
suggest
associ
hhv
ipf
patient
ipf
rais
serum
antibodi
ebv
compar
none
diseas
control
nonipf
ild
wherea
serum
antibodi
hsv
cmv
within
normal
rang
patient
number
studi
report
increas
frequenc
ebv
lung
biopsi
bronchoalveolar
lavag
bal
sampl
patient
ipf
compar
control
folcik
colleagu
found
dna
herp
viru
saimiri
pathogen
squirrel
monkey
infect
human
regener
epitheli
cell
ipf
biopsi
compar
none
control
lung
epitheli
cell
notabl
sequenc
herpesviru
saimiri
gene
extract
ipf
sampl
match
publish
viral
sequenc
consist
ipf
repres
herpesviru
saimiriinduc
pulmonari
fibrosi
hhvinfect
epitheli
cell
patient
ipf
evid
endoplasm
reticulum
stress
apoptosi
suggest
mechanist
link
viral
infect
develop
ipf
recent
kropski
cowork
found
increas
herp
viru
dna
cellfre
bal
along
evid
herp
viru
antigen
express
alveolar
epitheli
cell
asymptomat
rel
patient
famili
ipf
suggest
alveolar
epithelium
individu
risk
ipf
may
infect
herp
virus
well
diseas
becom
clinic
evid
howev
larg
extent
data
surround
role
viral
infect
pathogenesi
ild
remain
conflict
inconclus
initi
studi
investig
role
lung
microbiom
trigger
cofactor
develop
progress
ipf
base
culturedepend
techniqu
richter
et
al
investig
bacteri
colon
lower
airway
patient
wegen
granulomatosi
wg
n
ipf
n
healthi
control
n
pathogen
commonli
grown
bal
fluid
patient
wg
ipf
specif
author
observ
pathogen
growth
eg
haemophilu
influenza
haemophilu
parainfluenza
streptococcu
pneumonia
moraxella
catarrhali
pseudomona
aeruginosa
proteu
mirabili
ipf
patient
suggest
occult
bacteri
infect
may
contribut
develop
ipf
garzoni
colleagu
employ
ultradeep
rrna
gene
sequenc
cultureindepend
techniqu
character
microbiota
upper
use
oropharyng
swab
lower
use
bal
fluid
respiratori
tract
patient
ild
five
idiopath
interstiti
pneumonia
iip
six
noniip
ild
seven
sarcoidosi
six
immunocompromis
patient
pneumocysti
pneumonia
nine
healthi
control
author
establish
presenc
lower
airway
microbiota
domin
prevotellacea
streptococcacea
acidaminococcacea
observ
signific
betweengroup
differ
composit
airway
microbiota
correl
outcom
biochem
marker
estim
timeprogress
comet
ipf
studi
first
truli
evalu
lung
microbiom
patient
moder
sever
ipf
n
mean
forc
vital
capac
fvc
mean
diffus
capac
lung
carbon
monoxid
dlco
although
lack
control
group
repres
import
weak
studi
commonli
identifi
bacteria
prevotella
veillonella
escherichia
spp
wellknown
inhabit
healthi
respiratori
microbiom
moreov
presenc
specif
streptococcu
sp
oper
taxonom
unit
staphylococcu
sp
strongli
associ
diseas
progress
defin
composit
death
acut
exacerb
lung
transplant
rel
declin
fvc
dlco
week
studi
period
patient
experienc
diseas
progress
notabl
patient
predominantli
either
streptococcu
otu
staphylococcu
otu
howev
enrich
streptococcu
otu
staphylococcu
otu
found
less
half
patient
impli
organ
alon
fulli
explain
diseas
pathogenesi
progress
molyneaux
colleagu
prospect
explor
lung
microbiom
patient
ipf
draw
comparison
healthi
diseas
copd
control
demonstr
statist
signific
twofold
higher
bacteri
burden
bal
patient
ipf
n
compar
patient
copd
n
healthi
control
n
furthermor
perhap
interestingli
bacteri
burden
baselin
predict
rate
function
declin
risk
death
notabl
bacteri
burden
lower
ipf
patient
carri
mutant
allel
known
risk
factor
ipf
yet
predictor
longer
surviv
patient
establish
diseas
theoret
observ
would
suggest
exist
least
two
distinct
pathogenet
pathway
lead
alveolar
injuri
ipf
one
involv
bacteri
overload
noncarri
mutant
variant
anoth
carri
allel
overexpress
distal
airwayalveolar
junction
result
increas
local
exposur
aberr
cellular
respons
bacteri
stimuli
well
increas
bacteri
burden
author
identifi
increas
read
potenti
pathogen
haemophilu
streptococcu
neisseria
veillonella
spp
ipf
patient
compar
healthi
control
unabl
identifi
bacteri
commun
structur
composit
differ
ipf
patient
stabl
progress
diseas
intrigu
associ
clinic
outcom
bacteri
burden
independ
valid
comet
author
dwyer
colleagu
employ
digit
droplet
pcr
sensit
measur
previou
studi
clearli
replic
find
subject
progress
diseas
higher
bacteri
burden
time
diagnosi
observ
find
hold
true
independ
cohort
use
multipl
bacteri
quantif
platform
strengthen
associ
bacteri
burden
surviv
ipf
studi
chang
bacteri
burden
also
associ
reduct
microbi
divers
often
associ
diseas
proinflammatori
profibrot
signal
airway
work
comet
author
perform
subanalysi
compar
microbiota
ipf
bal
fluid
n
ipf
radiograph
featur
eg
presenc
absenc
honeycomb
cardin
radiolog
histopatholog
featur
ipf
dickson
colleagu
found
associ
bacteri
burden
presenc
radiolog
honeycomb
identifi
slight
differ
overal
bacteri
commun
structur
base
radiolog
chang
clear
candid
bacteria
drive
differ
identifi
taken
togeth
observ
suggest
lung
microbi
commun
patient
ipf
differ
significantli
base
diseas
morpholog
sever
prospect
work
geograph
variat
lung
microbiom
ipf
need
bacteria
potenti
caus
epitheli
cell
injuri
airway
directli
indirectli
either
induc
host
immun
respons
activ
wound
heal
cascad
follow
chronic
lowlevel
antigen
stimulu
howev
despit
grow
evid
associ
causal
signific
alter
lung
microbiota
ipf
remain
elus
integr
analysi
host
transcriptom
microbi
signatur
demonstr
appar
host
respons
presenc
alter
abund
microbiom
suggest
bacteri
commun
lower
airway
may
act
persist
stimuli
repetit
alveolar
injuri
ipf
addit
hostmicrobiom
interact
shown
influenc
fibroblast
respons
progressionfre
surviv
although
remain
correl
rather
causal
relationship
recent
dwyer
colleagu
valid
find
lung
bacteri
burden
predict
diseas
progress
patient
ipf
divers
composit
microbiota
correl
increas
alveolar
profibrot
cytokin
effort
understand
mechan
behind
chang
author
employ
mous
model
pulmonari
fibrosi
littl
known
effect
bleomycininduc
fibrosi
respiratori
microbiom
mous
model
author
first
set
character
chang
bacteri
burden
observ
bacteri
divers
increas
rapidli
inflammatori
phase
model
persist
develop
fibrosi
occur
suggest
lung
dysbiosi
preced
develop
fibrosi
mous
model
studi
impact
microbiom
model
author
employ
germfre
condit
steril
condit
bleomycin
exposur
result
similar
level
fibrosi
absenc
microbiota
protect
mortal
limit
anim
model
ipf
notwithstand
studi
provid
potenti
mechanist
link
lung
bacteri
burden
diseas
pathogenesi
progress
pulmonari
fibrosi
contrast
aforement
studi
suggest
abnorm
bacteri
burden
composit
lung
patient
ipf
compar
diseas
healthi
control
kitsio
colleagu
found
surprisingli
low
bacteri
signal
subpleur
lower
lobe
lung
explant
endstag
patient
ipf
notabl
low
signal
ipf
patient
similar
neg
control
strike
contrast
abund
pathogen
identifi
cystic
fibrosi
lung
explant
bia
regard
endstag
popul
use
andor
analysi
subpleur
honeycomb
region
bacteri
load
could
lower
may
account
conflict
result
acut
exacerb
ipf
aeipf
episod
acut
respiratori
worsen
median
surviv
follow
event
approxim
three
four
month
accord
recent
revis
definit
diagnost
criteria
either
idiopath
trigger
instanc
infect
cardiac
failur
fluid
overload
extraparenchym
caus
pulmonari
embol
pneumothorax
pleural
effus
need
exclud
notabl
origin
diagnost
criteria
aeipf
requir
event
idiopath
studi
publish
revis
document
conduct
patient
without
overt
clinic
infect
sever
studi
report
associ
subclin
occult
viral
infect
aeipf
although
causal
role
associ
remain
proven
studi
subject
aeipf
fail
clearli
identifi
viral
infecti
aetiolog
acut
event
vast
major
patient
addit
subject
n
neg
bacteri
cultur
neg
viral
serolog
pcr
analysi
bal
fluid
patient
test
posit
common
respiratori
virus
eg
parainfluenza
n
rhinoviru
n
coronaviru
n
virus
detect
bal
fluid
stabl
patient
n
panvir
microarray
reveal
presenc
hsv
n
ebv
n
torqu
teno
viru
ttv
viru
n
patient
ae
stabl
diseas
group
p
ttv
infect
present
similar
percentag
diseas
control
acut
lung
injuri
deep
sequenc
subset
ae
case
confirm
presenc
ttv
identifi
addit
virus
japanes
studi
patient
ae
ild
includ
ipf
found
virus
respiratori
sampl
includ
n
plu
cmv
n
proport
viru
infect
ipf
nonipf
ild
group
similar
moreov
probabl
surviv
day
lower
viru
posit
group
viru
isol
predict
surviv
question
clinic
relev
find
recent
viral
sequenc
detect
nasopharyng
swab
patient
aeipf
case
stabl
diseas
p
aeipf
show
increas
level
inflammatori
cytokin
ifngamma
mig
compar
ipf
patient
stabl
diseas
control
hhv
influenza
viru
account
major
viral
burden
interestingli
aeipf
follow
influenza
vaccin
report
recent
littl
focu
role
bacteri
infect
trigger
aeipf
molyneaux
colleagu
use
cultureindepend
techniqu
explor
chang
bal
microbiota
patient
stabl
ipf
n
subject
experienc
aeipf
n
despit
neg
bal
bacteri
cultur
viru
screen
bacteri
burden
patient
aeipf
four
time
higher
patient
stabl
diseas
addit
bacteri
commun
patient
stabl
diseas
contain
streptococcu
prevotella
veillonella
haemophilu
psedomona
follow
aeipf
microbiota
chang
substanti
increas
campylobact
stenotrophomona
spp
decreas
veillonella
sp
recent
weng
colleagu
look
presenc
pathogen
specif
igm
microbi
pathogen
sputum
sequenc
pathogen
nasopharyng
swab
ipf
patient
stabl
diseas
aeipf
control
bacteri
igm
higher
stabl
ipf
control
aeipf
stabl
patient
mycoplasma
display
highest
igm
posit
rate
diseas
subset
respect
thirtyeight
differ
bacteri
strain
mainli
gramneg
detect
sputum
patient
ipf
total
detect
rate
differ
patient
aeipf
stabl
diseas
versu
respect
taken
togeth
observ
suggest
alter
pulmonari
microbiom
play
caus
role
least
case
aeipf
howev
theoret
higher
bacteri
load
alter
microbiom
found
ae
could
consequ
rather
caus
diffus
alveolar
damag
characterist
ae
ideal
futur
studi
collect
pair
sampl
patient
stabl
acut
event
prove
chang
baselin
microbiota
forc
relationship
associ
causat
despit
rational
use
ipf
studi
investig
efficaci
antibiot
set
follow
pilot
studi
patient
progress
fibrot
lung
diseas
cotrimoxazol
treatment
improv
fvc
shuttl
walk
distanc
reduc
oxygen
desatur
exercis
medic
research
council
mrc
dyspnoea
score
st
georg
respiratori
questionnair
sghrq
symptom
score
larger
random
doubleblind
placebocontrol
trial
design
assess
safeti
efficaci
oral
cotrimoxazol
mg
twice
daili
month
addit
usual
treatment
patient
fibrot
iip
definit
probabl
ipf
n
definit
probabl
nonspecif
interstiti
pneumonia
nsip
n
signific
betweengroup
differ
seen
regard
chang
fvc
primari
outcom
similarli
differ
cotrimoxazol
placebo
group
observ
term
chang
dlco
walk
test
mrc
dyspnoea
score
intentiontotreat
analysi
howev
perprotocol
analysi
cotrimoxazol
treatment
compar
placebo
associ
signific
improv
euroqol
base
util
measur
health
state
signific
reduct
percentag
patient
requir
increas
oxygen
therapi
signific
reduct
allcaus
mortal
death
cotrimoxazol
group
versu
placebo
group
p
hazard
ratio
hr
author
specul
reduc
mortal
cotrimoxazol
group
could
due
reduct
rate
respiratori
infect
fact
patient
receiv
usual
treatment
immunosuppress
time
studi
still
therapeut
option
patient
like
die
placebo
group
wherea
baselin
immunosuppress
therapi
effect
mortal
cotrimoxazol
group
studi
howev
import
drawback
includ
lack
true
placebo
arm
high
dropout
rate
due
side
effect
mostli
rash
nausea
among
patient
receiv
cotrimoxazol
versu
placebo
group
phase
iii
doubl
blind
randomis
placebocontrol
multicentr
clinic
trial
oral
cotrimoxazol
versu
placebo
patient
moder
sever
ipf
current
underway
efficaci
mechan
evalu
treat
idiopath
pulmonari
fibrosi
addit
cotrimoxazol
eudract
number
primari
outcom
time
death
caus
lung
transplant
first
nonelect
hospit
admiss
potenti
benefit
macrolid
also
evalu
ipf
patient
although
retrospect
rel
small
cohort
singlecentr
studi
kawamura
colleagu
compar
efficaci
azithromycin
mgday
five
day
fluoroquinolonebas
regimen
histor
control
group
patient
idiopath
aeipf
mortal
significantli
lower
among
patient
treat
azithromycin
n
treat
fluoroquinolon
n
versu
p
hr
multivari
analysi
confirm
azithromycin
use
independ
correl
mortal
recent
retrospect
observ
studi
macaluso
cowork
look
ipf
patient
receiv
prophylact
azithromycin
mg
three
time
weekli
evalu
longterm
effect
rate
hospit
end
compar
number
allcaus
nonelect
hospit
antibiot
cours
month
preced
follow
treatment
initi
found
hospit
admiss
seven
versu
antibiot
cours
versu
significantli
lower
year
institut
prophylact
azithromycin
overal
azithromycin
safe
well
toler
data
suggest
potenti
clinic
benefit
prophylact
azithromycin
patient
ipf
howev
mechan
antibacteri
antiinflammatori
macrolid
reduc
risk
hospit
event
patient
ipf
remain
elucid
tabl
summar
current
ongo
clinic
trial
evalu
efficaci
safeti
antibiot
ipf
balanc
intestin
microbi
commun
essenti
develop
mainten
immun
function
health
respiratori
microbiom
develop
tandem
gut
clear
crosstalk
two
compart
axi
manipul
gut
microbiom
chang
diet
drug
alter
microbiom
lung
provid
benefici
effect
asthma
protect
respiratori
virus
direct
seed
bacteria
gastrointestin
tract
airway
may
play
role
shape
respiratori
microbiom
trigger
local
immun
respons
figur
howev
clear
gastrointestin
tract
direct
immun
respons
remot
environ
system
dissemin
bacteri
metabolit
via
bloodstream
shown
shortchain
fatti
acid
scfa
benefici
effect
dietaryfibr
ferment
product
well
document
number
chronic
inflammatori
diseas
dysbiosi
gut
microbiota
associ
number
local
system
condit
includ
respiratori
diseas
case
asthma
wherein
gut
microbiota
patient
enrich
histamineproduc
bacteria
compar
healthi
control
dysbiot
gut
microbiota
also
shown
patient
system
sclerosi
particularli
extraintestin
manifest
includ
lung
fibrosi
silicosi
experiment
system
sclerosi
manipul
intestin
microbiota
earlylif
antibiot
administr
associ
dysregul
tcell
respons
lung
alter
express
fibrosisrel
gene
moreov
earlylif
dysbiosi
associ
adultonset
lung
fibrosi
hypothesi
earlylif
intestin
dysbiosi
durabl
confer
suscept
lateonset
lung
fibrosi
human
diseas
intrigu
howev
role
axi
pulmonari
inflamm
studi
littl
known
impact
microbi
metabolit
develop
pulmonari
fibrosi
sever
studi
suggest
alter
microbiom
burden
divers
composit
may
contribut
diseas
pathogenesi
progress
acut
exacerb
mortal
ipf
mechanist
link
derang
lung
microbiom
ipf
develop
progress
establish
microbiom
manipul
aim
restor
healthi
microbiom
commun
soon
repres
potenti
therapeut
intervent
ipf
although
holist
approach
account
mani
factor
drive
diseas
develop
progress
acut
worsen
like
truli
efficaci
whether
lung
microbiom
manipul
use
antibiot
probiot
extrins
microb
administ
interest
health
prebiot
molecul
promot
specif
bacteri
growth
unknown
regardless
microbiom
manipul
target
pathogen
microb
without
alter
residenti
member
microbi
commun
would
even
challeng
